MiniMed Group, Inc. cash flow statement MMED

In fiscal 2026, which ended Apr 24, 2026, MiniMed Group, Inc. used $197.0 million of cash from operations. It spent $223.0 million on capital expenditures. Free cash flow was negative, at -$420.0 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2027
Jul 31, 2026
FY 2026
Apr 24, 2026
Operating
Depreciation and amortization
—
156
Stock-based compensation
—
46
Operating cash flow
—
-197
Investing
Capital expenditures
—
223
Investing cash flow
—
-233
Financing
Financing cash flow
—
716
Change in cash
Net change in cash
—
287
Free cash flow
—
-420
Per share
Free cash flow per share
—
-1.64
Ratios
Free cash flow margin
—
-13.54%
Capital expenditures to revenue
—
7.19%
Stock-based compensation to revenue
—
1.48%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
MMED (Nasdaq), MMEDV (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Northridge, CA
SEC filer status
Non-accelerated filer
SEC CIK
2062583
Former names
MDT Sub Holdings, Inc. (until May 30, 2025)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.